Literature DB >> 28229425

Optimal Environmental Stiffness for Stem Cell Mediated Ischemic Myocardium Repair.

Honghai Liu1, Christian Paul1, Meifeng Xu2.   

Abstract

Cardiovascular diseases related to myocardial infarction (MI) contribute significantly to morbidity and mortality worldwide. The loss of cardiomyocytes during MI is a key factor in the impairment of cardiac-pump functions. Employing cell transplantation has shown great potential as a therapeutic approach in regenerating ischemic myocardium. Several studies have suggested that the therapeutic effects of stem cells vary based on the timing of cell administration. It has been clearly established that the myocardium post-infarction experiences a time-dependent stiffness change, and many studies have highlighted the importance of stiffness (elasticity) of microenvironment on modulating the fate and function of stem cells. Therefore, this chapter outlines our studies and other experiments designed to establish the optimal stiffness of microenvironment that maximizes benefits for maintaining cell survival, promoting phenotypic plasticity, and improving functional specification of the engrafted stem cells.

Entities:  

Keywords:  Hydrogel; Myocardial infarction; Stem cell therapy; Stiffness of microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28229425      PMCID: PMC5637729          DOI: 10.1007/978-1-4939-6756-8_23

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  68 in total

Review 1.  Tissue cells feel and respond to the stiffness of their substrate.

Authors:  Dennis E Discher; Paul Janmey; Yu-Li Wang
Journal:  Science       Date:  2005-11-18       Impact factor: 47.728

2.  Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial.

Authors:  Gerd P Meyer; Kai C Wollert; Joachim Lotz; Jan Steffens; Peter Lippolt; Stephanie Fichtner; Hartmut Hecker; Arnd Schaefer; Lubomir Arseniev; Bernd Hertenstein; Arnold Ganser; Helmut Drexler
Journal:  Circulation       Date:  2006-03-06       Impact factor: 29.690

Review 3.  Substrates for cardiovascular tissue engineering.

Authors:  C V C Bouten; P Y W Dankers; A Driessen-Mol; S Pedron; A M A Brizard; F P T Baaijens
Journal:  Adv Drug Deliv Rev       Date:  2011-01-25       Impact factor: 15.470

4.  Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation.

Authors:  Konstantinos E Hatzistergos; Henry Quevedo; Behzad N Oskouei; Qinghua Hu; Gary S Feigenbaum; Irene S Margitich; Ramesh Mazhari; Andrew J Boyle; Juan P Zambrano; Jose E Rodriguez; Raul Dulce; Pradip M Pattany; David Valdes; Concepcion Revilla; Alan W Heldman; Ian McNiece; Joshua M Hare
Journal:  Circ Res       Date:  2010-07-29       Impact factor: 17.367

5.  Tissue-engineered, hydrogel-based endothelial progenitor cell therapy robustly revascularizes ischemic myocardium and preserves ventricular function.

Authors:  Pavan Atluri; Jordan S Miller; Robert J Emery; George Hung; Alen Trubelja; Jeffrey E Cohen; Kelsey Lloyd; Jason Han; Ann C Gaffey; John W MacArthur; Christopher S Chen; Y Joseph Woo
Journal:  J Thorac Cardiovasc Surg       Date:  2014-06-28       Impact factor: 5.209

6.  Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction.

Authors:  Jennifer M Singelyn; Priya Sundaramurthy; Todd D Johnson; Pamela J Schup-Magoffin; Diane P Hu; Denver M Faulk; Jean Wang; Kristine M Mayle; Kendra Bartels; Michael Salvatore; Adam M Kinsey; Anthony N Demaria; Nabil Dib; Karen L Christman
Journal:  J Am Coll Cardiol       Date:  2012-02-21       Impact factor: 24.094

7.  Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction.

Authors:  Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

8.  Embryonic cardiomyocytes beat best on a matrix with heart-like elasticity: scar-like rigidity inhibits beating.

Authors:  Adam J Engler; Christine Carag-Krieger; Colin P Johnson; Matthew Raab; Hsin-Yao Tang; David W Speicher; Joseph W Sanger; Jean M Sanger; Dennis E Discher
Journal:  J Cell Sci       Date:  2008-10-28       Impact factor: 5.285

9.  Harnessing traction-mediated manipulation of the cell/matrix interface to control stem-cell fate.

Authors:  Nathaniel Huebsch; Praveen R Arany; Angelo S Mao; Dmitry Shvartsman; Omar A Ali; Sidi A Bencherif; José Rivera-Feliciano; David J Mooney
Journal:  Nat Mater       Date:  2010-04-25       Impact factor: 43.841

10.  Enhanced angiogenic and cardiomyocyte differentiation capacity of epigenetically reprogrammed mouse and human endothelial progenitor cells augments their efficacy for ischemic myocardial repair.

Authors:  Melissa A Thal; Prasanna Krishnamurthy; Alexander R Mackie; Eneda Hoxha; Erin Lambers; Suresh Verma; Veronica Ramirez; Gangjian Qin; Douglas W Losordo; Raj Kishore
Journal:  Circ Res       Date:  2012-05-15       Impact factor: 17.367

View more
  1 in total

Review 1.  ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure.

Authors:  Rosalinda Madonna; Linda W Van Laake; Hans Erik Botker; Sean M Davidson; Raffaele De Caterina; Felix B Engel; Thomas Eschenhagen; Francesco Fernandez-Aviles; Derek J Hausenloy; Jean-Sebastien Hulot; Sandrine Lecour; Jonathan Leor; Philippe Menasché; Maurizio Pesce; Cinzia Perrino; Fabrice Prunier; Sophie Van Linthout; Kirsti Ytrehus; Wolfram-Hubertus Zimmermann; Peter Ferdinandy; Joost P G Sluijter
Journal:  Cardiovasc Res       Date:  2019-03-01       Impact factor: 10.787

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.